scout
News|Videos|June 19, 2025

An All-Oral Regimen of Decitabine-Cedazuridine (DEC-C) Plus Venetoclax (VEN) in Patients With Newly Diagnosed AML Ineligible for Intensive Induction Chemotherapy: Results From a Phase 2 Cohort of 101 Patients

Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME